XOMA Corporation (XOMA): Market Capitalization-to-Revenue Ratio

Brandmark of XOMA Royalty (XOMA)

XOMA Royalty (XOMA) stock dynamics depend on the outcome of partners' clinical trials, which creates a risk of asset impairment. The revenue multiple on the GURU.Markets daily price chart reflects these fluctuations, where the indicator value reaches 14.60. XOMA Royalty (XOMA) acts as a financial catalyst for the biotech sector by acquiring rights to future payments and maintains its status as a trusted partner with a diversified license portfolio.

XOMA XOMA Royalty: P/S Multiple in the range 07/04/2022 - 07/25/2026

Metric breakdowns and analytics for XOMA Royalty (XOMA)

- stock value and consensus price forecast:
Stock Price XOMA Corporation|XOMA - Price Target Chart
- stock exchange capitalization data:
Market Value XOMA|XOMA - Enterprise Value
- book capitalization indicators:
Accounting Value per Share XOMA Royalty|XOMA - Book Capitalization|Market-to-Book Ratio xoma.com|XOMA - Cumulative Company Assets
- debt obligations and liquidity statistics:
Debt to Equity Ratio XOMA Royalty|XOMA - Long-Term Debt to Equity|Current Liabilities to Capital XOMA Corporation|XOMA - Company Debts|Debt to Book Value XOMA|XOMA - Company Long-Term Debts|Company Short-Term Debts XOMA Royalty|Intermediate Coverage Ratio xoma.com
- business earnings and investment ratios data:
XOMA - Company Net Income|Expected Net Income XOMA Royalty|XOMA - Price to Earnings Ratio|Projected Price to Earnings Ratio XOMA Corp|XOMA - Price/Earnings to Growth Multiple|Company Value to EBITDA XOMA|XOMA - Operating profit EBITDA|Net earnings per share (EPS TTM) XOMA Royalty|XOMA - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last twelve months xoma.com|XOMA - Net earnings per share growth this year|Projected earnings per share increase next year XOMA Royalty
- issuer revenue and sales details:
XOMA - Company Sales|Company Expected Sales Volume XOMA Corp|XOMA - Market Cap to Revenue|Market Cap to Projected Revenue XOMA Royalty|XOMA - Sales Growth YoY (Last Twelve Months)
Fundamental company analysis:XOMA (XOMA Corp)
Manufactured products of XOMA Corp

XOMA Royalty operates under a debt-free model where revenues depend on external regulatory approvals of partners' drugs. This metric, calculated as the ratio of market capitalization to annual revenue, measures the cost of one dollar of sales, allowing investors to determine the degree of overpayment relative to the issuer's actual cash flows through the company's revenue valuation on GURU.Markets.

Competing companies

TPL (Texas Pacific Land Corporation) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Royalty Pharma Corp RPRX|Market Capitalization-to-Revenue Ratio VNOM|Black Stone Minerals LP - P/S Multiple|Price to Sales Northern Oil and Gas, Inc.|DMLP: P/S Multiple|SBR - Price-to-Revenue Coefficient|VTS (Vitesse Oil) - P/S Multiple|Price to Sales Permian Basin Royalty PBT|Price-to-Revenue Ratio TXO Partners LP (TXO)|GRNT (Granite Ridge Resources) - Market Capitalization-to-Revenue Ratio|San Juan Basin Royalty Trust - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio STEX|SRL - Price-to-Revenue Ratio|Price-to-Revenue Coefficient MV Oil Trust, Inc. MVO|PVL: P/S Multiple|Market Cap to Revenue Ratio VOC|Market Cap to Revenue CRT|Market Cap to Revenue PermRock Royalty Trust Inc (PRT)|Market Cap to Revenue RMCO (royaltymgmtcorp.com)|CKX Lands Inc. - Market Cap to Revenue Ratio|P/S Multiple MTR (Mesa Royalty Trust, Inc.)|BP Prudhoe Bay Royalty Trust Inc (BPT) - Price to Sales|phxmin.com - P/S Multiple|STR - P/S Multiple